Transolam

Transolam facilitates personal investments and syndications with select investors, focusing on launching and building successful businesses in the U.S. and Israel.

Venture Capital Active Beverly Hills, United States
Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
total disclosed, rounds participated
Stages
Pre-Seed, Seed, A Round

About

Transolam LLC was founded by Behzad Kianmahd and Daniel Nazarian to facilitate their personal investments and to leverage their strong deal flow through syndications with select investors in their networks. The founders and co-investors are passionate about launching and building successful businesses in the U.S. and Israel. They have extensive experience fostering the success of early-stage companies as founders, board members, advisors, investors, mentors, and fundraisers. Their deal flow is enhanced by active involvement in local, national, and international startup ecosystems, including an MIT-related Fund and TAU Ventures, the first venture capital fund established by Tel Aviv University to invest in early-stage, cutting-edge technologies.

Portfolio

No portfolio companies in this dataset yet.

Q&A

What is Transolam's primary investment focus?
Transolam is a Venture Capital fund that invests in early-stage startups in Israel and the USA, focusing on Seed, Angel, Bridge, and Round A financing.
When was Transolam founded?
Transolam was founded in 2008.
Who are the managing members at Transolam?
The managing members at Transolam are Behzad Kianmahd and Daniel Nazarian. Daniel Nazarian is also a founder of the firm.
What investment stages does Transolam target?
Transolam targets Pre-Seed, Seed, and A Round investment stages.
Where is Transolam headquartered?
Transolam is headquartered in California, United States.
Does Transolam have a presence on LinkedIn?
Yes, Transolam maintains a presence on LinkedIn at https://www.linkedin.com/company/103339226.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)